Authors :
Himani Mevada; Dr. Dhiren L. Chaudhary; Ami H. Patel; Dr. Indermeet Singh Anand
Volume/Issue :
Volume 11 - 2026, Issue 1 - January
Google Scholar :
https://tinyurl.com/3jjnnexj
Scribd :
https://tinyurl.com/mr4342t4
DOI :
https://doi.org/10.38124/ijisrt/26jan1600
Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.
Abstract :
Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder caused by the abnormal reflux of gastric contents into the esophagus, resulting in symptoms and potential mucosal injury. Its pathogenesis involves lower esophageal sphincter dysfunction, impaired esophageal clearance, delayed gastric emptying, and exposure to acidic and nonacidic refluxate. GERD presents as erosive or non-erosive disease, with varying risks of complications such as Barrett’s esophagus. Management includes lifestyle modifications and pharmacological therapy, with proton pump inhibitors as firstline agents. Emerging therapies, including potassium-competitive acid blockers, offer alternative approaches. This review highlights the epidemiology, pathophysiology, clinical features, and current treatment strategies for GERD.
Keywords :
Gastroesophageal Reflux Disease; Risk Factors; Proton Pump Inhibitors; Potassium-Competitive Acid Blockers.
References :
- Dipiro J.T, Wells B.G, Schwinghammer T.L, Dipiro C.V., Pharmacotherapy Handbook, 7th Edn; McGraw-Hill Companies, Inc, United States, 2009,pp 263.
- Antunes C., Aleem A., Curtis S.A., “ Gastroesophageal Reflux Disease,” Statpearls.2023.
- Mayo clinic, “Gastroesophageal reflux disease (GERD)”, January 2026. https://www.mayoclinic.org/diseases-conditions/gerd/symptoms-causes/syc-20361940
- Maret-Ouda J., Markar S. R., Lagergren J., “ Gastroesophageal reflux disease,” JAMA.2020;324;(24):2565.
- Ahmed A., Clarke J.O., “Proton Pump Inhibitors,”Statpearls,2023.
- Drugbank, “Vonoprazan”, January 2026. https://go.drugbank.com/drugs/DB11739
- Liang S.W, Wong M., Chih-Hsun Yi., Liu T., Lei W., Hung J., Lin L., Rogers B.D., Linchen C.,“Current advances in the diagnosis and management of gastroesophageal reflux disease,” Tzu Chi Med. J.2022,34(4),402-408.
Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder caused by the abnormal reflux of gastric contents into the esophagus, resulting in symptoms and potential mucosal injury. Its pathogenesis involves lower esophageal sphincter dysfunction, impaired esophageal clearance, delayed gastric emptying, and exposure to acidic and nonacidic refluxate. GERD presents as erosive or non-erosive disease, with varying risks of complications such as Barrett’s esophagus. Management includes lifestyle modifications and pharmacological therapy, with proton pump inhibitors as firstline agents. Emerging therapies, including potassium-competitive acid blockers, offer alternative approaches. This review highlights the epidemiology, pathophysiology, clinical features, and current treatment strategies for GERD.
Keywords :
Gastroesophageal Reflux Disease; Risk Factors; Proton Pump Inhibitors; Potassium-Competitive Acid Blockers.